MicroQuin

MicroQuin is a preclinical biotechnology company founded in 2018 that focuses on developing new therapies for breast cancer. MicroQuin believes that the core of all diseases lies in changes in interleukin-1β converting enzyme (ICE), and all cancers induce extreme ICE. By modulating ICE, new cancer therapies can be created, and the company is achieving this goal through proprietary small molecules, synthetic peptides, and gene therapies.